Nottingham, UK, 1st April 2009 – Sygnature Chemical Services Ltd., a leading provider of medicinal and synthetic chemistry and chemical library services, is pleased to announce the appointment of Dr. Paul Clewlow as Senior Vice-President, Business Development, and as an executive member of the Board of Directors.
Dr. Simon Hirst, Chief Executive Officer of Sygnature CS commented, “Paul is a great addition to Sygnature’s senior management team. He has over twenty years’ experience in business development through his involvement with pharmaceutical companies and CROs, and will be invaluable in helping us to chart the future direction of Sygnature CS. Paul joins the company at exciting time in its evolution. Sales have doubled over the past year and we have recruited experienced chemists to occupy the £1M expansion of our research facility. The prospects for further growth are excellent and I am sure Paul will make a significant contribution to the success of Sygnature’s business.”
Dr. Paul Clewlow added, “I am delighted to have joined Sygnature CS at a time when the company is well placed to take advantage of the increasing opportunities presented to it by the pharmaceutical industry. Drug discovery and development is an expensive and time-consuming process, the chances of successfully producing a new marketed drug remain small, and the industry is going through an unprecedented period of change and uncertainty. In the face of these challenges, companies undertaking pharmaceutical R&D require, more than ever, a trusted strategic CRO partner, with significant industry experience to increase the value of their drug discovery programmes, and accelerate them into development. I believe that Sygnature CS is that trusted partner, and I am looking forward to working with Simon and his colleagues.”
About Sygnature Chemical Services Ltd.
Sygnature Chemical Services was founded in 2004 and is rapidly becoming one of the United Kingdom’s leading providers of medicinal chemistry, chemical library and computational chemistry services. Sygnature’s team of pharmaceutical industry experienced chemists have the skills and resources to discover hits, using a combination of computational chemistry and knowledge-based design strategies, and then rapidly optimise these early stage compounds to deliver development candidates to clients. Sygnature CS has the capabilities and know-how to make a contract project successful, whether it requires medicinal chemistry, complex synthesis or routine compound handling operations.
Sygnature CS is located in Nottingham, UK, and occupies modern, start-of-the-art facilities in BioCity, one of Europe’s largest biosciences incubators. For more information, visit www.sygnaturechem.com.
